Key Performance
More- Earnings Score: N/A
- Momentum Score: 37
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSS
Beta Bionics (NASDAQ: BBNX) is facing a securities class action lawsuit for allegedly misleading investors about its iLet automated insulin delivery system. The company concealed thousands of safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required. An FDA warning letter in February 2026 revealed the violations, causing significant stock price declines during the class period of July 30, 2025 to February 24, 2026.
09/10/2026, 8:29 PM • GlobeNewswire
Bernstein Liebhard LLP has announced multiple shareholder class action lawsuits against Beta Bionics, Dick's Sporting Goods, and EquipmentShare.com for allegedly making materially false and misleading statements regarding their business operations and financial stability. Investors who purchased shares during specified periods are encouraged to contact the firm to discuss their rights and potential recovery.
09/08/2026, 1:42 PM • GlobeNewswire
A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The lawsuit claims the company failed to disclose serious safety deficiencies, quality management issues, and customer complaints involving serious injuries, thereby understating regulatory risks and misrepresenting the device's safety and efficacy.
09/07/2026, 1:54 PM • GlobeNewswire
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating Beta Bionics, Inc. for potential securities law violations concerning false or misleading statements about the company's growth trends, new patient starts, and business outlook. The investigation was prompted by Beta Bionics' January 8, 2026 disclosure of slower new patient start growth in Q4 2025, with only 5,581 new patient starts representing 36% year-over-year growth, a significant deceleration from the prior quarter's 68% growth rate.
09/05/2026, 10:16 AM • GlobeNewswire
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLC is investigating Beta Bionics, Inc. for potential securities law violations related to false or misleading statements about growth trends and new patient starts. The company reported Q4 2025 new patient starts of at least 5,581 (36% YoY growth) on January 8, 2026, which fell below analyst expectations and showed significant deceleration from the prior quarter's 68% growth rate, potentially causing investor losses.
07/30/2026, 8:48 AM • GlobeNewswire
Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations and breach of fiduciary duties. The investigation follows the company's January 8, 2026 announcement of fourth quarter 2025 results showing new patient starts of at least 5,581 (36% year-over-year growth), which fell short of analyst expectations and represented a significant slowdown from the prior quarter's 68% growth. The stock declined more than 35% following the announcement.
06/05/2026, 6:09 PM • GlobeNewswire
Robbins LLP is investigating Beta Bionics, Inc. for potential securities law violations and breach of fiduciary duties. The company reported Q4 2025 new patient starts of 5,581 (36% YoY growth), missing analyst expectations and showing a significant slowdown from the prior quarter's 68% growth. The stock declined over 35% following the January 9, 2026 announcement.
06/02/2026, 7:24 PM • GlobeNewswire
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into possible securities fraud at Beta Bionics, Inc. and may file a class action lawsuit. The company's stock plummeted 37.03% on January 9, 2026, following disclosure of preliminary Q4 2025 results showing a significant slowdown in new user acquisition, with year-over-year growth declining from 68% to 36%, triggering investor concerns about the company's long-term growth trajectory.
04/14/2026, 9:00 AM • GlobeNewswire
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Beta Bionics, CVRx, and Navan. Beta Bionics experienced a significant stock price decline of 37% following the announcement of slower-than-expected patient growth in Q4 2025, with new patient starts increasing 36% year-over-year compared to 68% in the prior quarter.
02/17/2026, 5:00 PM • GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Securities law firm Faruqi & Faruqi is investigating Beta Bionics for potentially issuing misleading statements or failing to disclose material information to investors. The investigation was prompted by a 37% stock plunge on January 9, 2026, following the company's announcement of lower-than-expected patient starts in Q4.
02/03/2026, 8:24 PM • GlobeNewswire
Scott+Scott is investigating whether Beta Bionics issued misleading statements or failed to disclose material information to investors. The company reported 5,581 new patient starts for Q4 2025, falling short of the 6,078 consensus expectation, causing the stock to plunge 37% to $20.14 on January 9, 2026.
01/21/2026, 6:15 PM • GlobeNewswire
The DJS Law Group is investigating Beta Bionics (NASDAQ: BBNX) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered after Beta Bionics announced lower-than-expected patient starts for Q4 on January 8, 2026, causing the stock to plummet 37% the following day.
01/15/2026, 1:36 AM • Benzinga
The Schall Law Firm is investigating Beta Bionics, Inc. for potential securities law violations, alleging the company issued false or misleading statements regarding patient starts. Beta Bionics disclosed lower-than-expected patient numbers on January 8, 2026, causing its stock to plummet over 37% the following day. The firm is seeking shareholders who suffered losses to participate in the investigation.
01/14/2026, 12:53 PM • GlobeNewswire
The Law Offices of Frank R. Cruz announced an investigation into Beta Bionics, Inc. for possible federal securities law violations. The investigation was triggered after Beta Bionics reported preliminary Q4 2025 results showing new patient starts growth of 36% year-over-year, down significantly from 68% in the prior quarter. The stock fell 37% ($11.85) to $20.15 per share on January 9, 2026, following the announcement.
01/12/2026, 4:55 PM • Benzinga
The DJS Law Group is investigating Beta Bionics (NASDAQ: BBNX) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered after Beta Bionics announced lower-than-expected patient starts for Q4 2025, causing the stock to plummet 37% on January 9, 2026.
01/12/2026, 7:15 AM • Benzinga
